thalidomide has been researched along with Myocardial Infarction in 8 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Myocardial Infarction: NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although thalidomide had no effect on cardiac function, our results suggest that intervention with thalidomide may have beneficial effects in post-MI HF by attenuating collagen accumulation and development of myocardial fibrosis." | 7.73 | Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. ( Attramadal, H; Aukrust, P; Bjørnerheim, R; Frøland, SS; Oie, E; Ueland, T; Vinge, LE; Wang, JE; Yndestad, A, 2006) |
| "Thalidomide was thought to be the cause of hypercoagulability and coronary spasm, so it was ceased immediately." | 5.42 | Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report. ( Jin, X; Yang, J; Zhang, S, 2015) |
| " The objective of this study was to quantify the risk of myocardial infarction (MI), stroke and revascularizations in people with apremilast-treated PsA compared with patients receiving other PsA treatments." | 4.02 | The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. ( Hagberg, KW; Jick, S; Persson, R; Qian, Y; Vasilakis-Scaramozza, C, 2021) |
| "Although thalidomide had no effect on cardiac function, our results suggest that intervention with thalidomide may have beneficial effects in post-MI HF by attenuating collagen accumulation and development of myocardial fibrosis." | 3.73 | Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. ( Attramadal, H; Aukrust, P; Bjørnerheim, R; Frøland, SS; Oie, E; Ueland, T; Vinge, LE; Wang, JE; Yndestad, A, 2006) |
| "Thalidomide was thought to be the cause of hypercoagulability and coronary spasm, so it was ceased immediately." | 1.42 | Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report. ( Jin, X; Yang, J; Zhang, S, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Persson, R | 2 |
| Hagberg, KW | 2 |
| Qian, Y | 2 |
| Vasilakis-Scaramozza, C | 2 |
| Jick, S | 2 |
| Cornell, RF | 1 |
| Goldhaber, SZ | 1 |
| Engelhardt, BG | 1 |
| Moslehi, J | 1 |
| Jagasia, M | 1 |
| Harrell, S | 1 |
| Rubinstein, SM | 1 |
| Hall, R | 1 |
| Wyatt, H | 1 |
| Piazza, G | 1 |
| Dauby, N | 1 |
| Coussement, J | 1 |
| Karakike, E | 1 |
| Ungureanu, C | 1 |
| De Wit, S | 1 |
| Payen, MC | 1 |
| Zhang, S | 2 |
| Yang, J | 1 |
| Jin, X | 1 |
| Yndestad, A | 1 |
| Vinge, LE | 1 |
| Bjørnerheim, R | 1 |
| Ueland, T | 1 |
| Wang, JE | 1 |
| Frøland, SS | 1 |
| Attramadal, H | 1 |
| Aukrust, P | 1 |
| Oie, E | 1 |
| Llambrich, A | 1 |
| Romero, D | 1 |
| Iranzo, P | 1 |
| Segura, S | 1 |
| Moreno, JA | 1 |
| Herrero, C | 1 |
1 trial available for thalidomide and Myocardial Infarction
| Article | Year |
|---|---|
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm | 2020 |
7 other studies available for thalidomide and Myocardial Infarction
| Article | Year |
|---|---|
The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database.
Topics: Age Factors; Aged; Antirheumatic Agents; Biological Products; Drug Therapy, Combination; Female; Fol | 2020 |
The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, P | 2021 |
Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers.
Topics: Acquired Immunodeficiency Syndrome; Adult; Coronary Angiography; Humans; Immune Reconstitution Infla | 2015 |
Myocardial infarction, symptomatic third degree atrioventricular block and pulmonary embolism caused by thalidomide: a case report.
Topics: Anticoagulants; Atrioventricular Block; Cardiac Pacing, Artificial; Coronary Angiography; Dermatolog | 2015 |
Lenalidomide: myocardial infarction.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Myocardial Infarction; Thalidomide | 2010 |
Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats.
Topics: Animals; Blood Pressure; Cytokines; Disease Models, Animal; Fibrosis; Gene Expression; Hydroxyprolin | 2006 |
Acute myocardial infarction in a patient with cutaneous lupus erythematosus treated with thalidomide.
Topics: Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Middle Aged; Myocardial In | 2007 |